Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 49

References for PMC Articles for PubMed (Select 21921206)

1.

Schistosoma mansoni antigen Sm-p80: Prophylactic efficacy of a vaccine formulated in human approved plasmid vector and adjuvant (VR 1020 and alum).

Zhang W, Ahmad G, Torben W, Siddiqui AA.

Acta Trop. 2011 May;118(2):142-51. doi: 10.1016/j.actatropica.2011.01.010. Epub 2011 Feb 18.

2.

Role of antibodies in Sm-p80-mediated protection against Schistosoma mansoni challenge infection in murine and nonhuman primate models.

Torben W, Ahmad G, Zhang W, Siddiqui AA.

Vaccine. 2011 Mar 9;29(12):2262-71. doi: 10.1016/j.vaccine.2011.01.040. Epub 2011 Jan 28.

4.

Vaccines to combat the neglected tropical diseases.

Bethony JM, Cole RN, Guo X, Kamhawi S, Lightowlers MW, Loukas A, Petri W, Reed S, Valenzuela JG, Hotez PJ.

Immunol Rev. 2011 Jan;239(1):237-70. doi: 10.1111/j.1600-065X.2010.00976.x. Review.

5.

CD23-bound IgE augments and dominates recall responses through human naive B cells.

Griffith QK, Liang Y, Onguru DO, Mwinzi PN, Ganley-Leal LM.

J Immunol. 2011 Jan 15;186(2):1060-7. doi: 10.4049/jimmunol.1002709. Epub 2010 Dec 15.

6.

Developing vaccines to combat hookworm infection and intestinal schistosomiasis.

Hotez PJ, Bethony JM, Diemert DJ, Pearson M, Loukas A.

Nat Rev Microbiol. 2010 Nov;8(11):814-26. doi: 10.1038/nrmicro2438. Review.

PMID:
20948553
7.

From innovation to application: social-ecological context, diagnostics, drugs and integrated control of schistosomiasis.

Utzinger J, N'goran EK, Caffrey CR, Keiser J.

Acta Trop. 2011 Sep;120 Suppl 1:S121-37. doi: 10.1016/j.actatropica.2010.08.020. Epub 2010 Sep 8. Review.

8.

Schistosomiasis elimination: lessons from the past guide the future.

Gray DJ, McManus DP, Li Y, Williams GM, Bergquist R, Ross AG.

Lancet Infect Dis. 2010 Oct;10(10):733-6. doi: 10.1016/S1473-3099(10)70099-2. Epub 2010 Aug 10.

PMID:
20705513
9.

Protective effects of Sm-p80 in the presence of resiquimod as an adjuvant against challenge infection with Schistosoma mansoni in mice.

Ahmad G, Zhang W, Torben W, Noor Z, Siddiqui AA.

Int J Infect Dis. 2010 Sep;14(9):e781-7. doi: 10.1016/j.ijid.2010.02.2266. Epub 2010 Jul 13.

10.

Increased IgG1, IFN-gamma, TNF-alpha and IL-6 responses to Mycobacterium tuberculosis antigens in patients with tuberculosis are lower after chemotherapy.

Mattos AM, Almeida Cde S, Franken KL, Alves CC, Abramo C, de Souza MA, L'Hotellier M, Alves MJ, Ferreira AP, Oliveira SC, Ottenhoff TH, Teixeira HC.

Int Immunol. 2010 Sep;22(9):775-82. doi: 10.1093/intimm/dxq429. Epub 2010 Jul 11.

11.

Increases in levels of schistosome-specific immunoglobulin E and CD23(+) B cells in a cohort of Kenyan children undergoing repeated treatment and reinfection with Schistosoma mansoni.

Black CL, Muok EM, Mwinzi PN, Carter JM, Karanja DM, Secor WE, Colley DG.

J Infect Dis. 2010 Aug 15;202(3):399-405. doi: 10.1086/653828.

12.

Sm-p80-based DNA vaccine made in a human use approved vector VR1020 protects against challenge infection with Schistosoma mansoni in mouse.

Zhang W, Ahmad G, Torben W, Siddiqui AA.

Parasite Immunol. 2010 Apr;32(4):252-8. doi: 10.1111/j.1365-3024.2009.01181.x.

PMID:
20398225
13.

Sm-p80-based DNA vaccine provides baboons with levels of protection against Schistosoma mansoni infection comparable to those achieved by the irradiated cercarial vaccine.

Zhang W, Ahmad G, Torben W, Noor Z, Le L, Damian RT, Wolf RF, White GL, Chavez-Suarez M, Podesta RB, Kennedy RC, Siddiqui AA.

J Infect Dis. 2010 Apr 1;201(7):1105-12. doi: 10.1086/651147.

14.

Parasites and poverty: the case of schistosomiasis.

King CH.

Acta Trop. 2010 Feb;113(2):95-104. doi: 10.1016/j.actatropica.2009.11.012. Epub 2009 Dec 4. Review.

15.

Essential and synergistic roles of IL1 and IL6 in human Th17 differentiation directed by TLR ligand-activated dendritic cells.

Benwell RK, Lee DR.

Clin Immunol. 2010 Feb;134(2):178-87. doi: 10.1016/j.clim.2009.09.013. Epub 2009 Oct 24.

PMID:
19854106
16.

Prime-boost and recombinant protein vaccination strategies using Sm-p80 protects against Schistosoma mansoni infection in the mouse model to levels previously attainable only by the irradiated cercarial vaccine.

Ahmad G, Zhang W, Torben W, Haskins C, Diggs S, Noor Z, Le L, Siddiqui AA.

Parasitol Res. 2009 Nov;105(6):1767-77. doi: 10.1007/s00436-009-1646-z. Epub 2009 Oct 7.

17.

Schistosomiasis in Africa: an emerging tragedy in our new global health decade.

Hotez PJ, Fenwick A.

PLoS Negl Trop Dis. 2009 Sep 29;3(9):e485. doi: 10.1371/journal.pntd.0000485. No abstract available.

18.

CD4 and CD8 distribution profile in individuals infected by Schistosoma mansoni.

Oliveira-Prado R, Caldas IR, Teixeira-Carvalho A, Andrade MV, Gazzinelli A, Correa-Oliveira R, Cunha-Melo JR.

Scand J Immunol. 2009 Jun;69(6):521-8. doi: 10.1111/j.1365-3083.2009.02247.x.

PMID:
19439013
19.

Protective and antifecundity effects of Sm-p80-based DNA vaccine formulation against Schistosoma mansoni in a nonhuman primate model.

Ahmad G, Zhang W, Torben W, Damian RT, Wolf RF, White GL, Chavez-Suarez M, Kennedy RC, Siddiqui AA.

Vaccine. 2009 May 11;27(21):2830-7. doi: 10.1016/j.vaccine.2009.02.096. Epub 2009 Mar 10.

20.

Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs.

Doenhoff MJ, Hagan P, Cioli D, Southgate V, Pica-Mattoccia L, Botros S, Coles G, Tchuem Tchuenté LA, Mbaye A, Engels D.

Parasitology. 2009 Nov;136(13):1825-35. doi: 10.1017/S0031182009000493. Epub 2009 Mar 13. Review.

PMID:
19281637
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk